CTI BioPharma Corp. (CTIC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.41+0.00 (+0.20%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.41
Bid0.39 x 4000
Ask1.12 x 300
Day's Range0.39 - 0.41
52wk Range0.25 - 1.46
1y Target EstN/A
Market Cap114.66M
P/E Ratio (ttm)-1.25
Avg Vol (3m)789,073
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • 5 Biotech Penny Stocks Smart Money Is Piling On
    Insider Monkey3 days ago

    5 Biotech Penny Stocks Smart Money Is Piling On

    Apart from technology, if there ever was a sector that short sellers were afraid to touch for fear of being squeezed out vehemently, it has to be biotech. The remarkable rally that the sector saw in the years following the financial crisis caused even the most bearish of bears to change their thesis on it […]

  • PR Newswire24 days ago

    CTI BioPharma Announces Retirement Of President And CEO

    SEATTLE, Oct. 3, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced that James A. Bianco, M.D, CTI BioPharma's President and Chief Executive Officer, has retired from the Company effective on October 2nd. At the request of the Board of Directors, Richard Love, a director of CTI BioPharma since 2007, has been appointed to serve as interim President and Chief Executive Officer.

  • PR Newswirelast month

    CTI BioPharma Granted 180 Day Extension By NASDAQ To Regain Compliance With Minimum Bid Price Rule

    SEATTLE, Sept. 22, 2016 /PRNewswire/ --  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced that on September 20, 2016, the NASDAQ Listing Qualifications staff granted the Company an additional 180 calendar day period, or until March 20, 2017, to regain compliance with the Minimum Bid Price Rule. CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers.